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Introduction
Approximately 75% of BRCA1 mutation-related breast
cancers are triple- negative breast cancers (TNBC). Recent
studies have proposed that individuals diagnosed with
(TNBC) before age 50 should be tested for BRCA1
mutation.
Aim of the study
To investigate the prevalence of germline BRCA1 founder
mutations in patients with TNBC and to find out appro-
priate indications for BRCA1 mutation testing in patients
with TNBC.
Material and methods
332 unselected patients with invasive breast cancer diag-
nosed between 2006- 2011 were identified from Pauls
Stradins Clinical University Hospital, Riga East University
hospital databases and clinical data from medical records
were retrospectively analyzed. All patients were tested for
the two common founder mutations in BRCA1 (4153delA
and 5382insC) in Latvia using a multiplex- specific poly-
merase chain reaction (PCR) assay.
Results
Of the 332 patients, 100 (30.1%) were identified as having
TNBC, the remaining patients 232 (69.9%) were identi-
fied as having other breast cancer subtypes. Among
patients with TNBC the BRCA1 mutations prevalence
were 17% (17 of 100 cases) compared to other patients’
group with 0.86% (2 of 232 cases) BRCA1 mutation pre-
valence (P= 0.001).
In the TNBC group BRCA1 mutation carriers were sig-
nificantly younger at diagnosis than non-carriers (median
age, 53.6 years versus 57 years, respectively; P= 0.043).
The vast majority of BRCA1 mutations within the TNBC
group were diagnosed in women under 50 years of age-
in 10 cases (58.8%), in 5 cases (29.4%) BRCA1 mutations
were detected between 50 and 65 years of age and in 2
cases (11.8%)- in patients older than age 65 years. In 113
of 332 (34%) patients without family history of cancer 2
of 19 BRCA1 mutations were found, in 219 (66%) of 332
patients with family history of cancer 17 of 19 BRCA1
mutations were detected, but BRCA1 mutation was not
statistically significant associated with a family history of
cancer and age of breast cancer diagnosis.
Conclusion
Our study data indicates a high prevalence of BRCA1
mutation in TNBC and suggests BRCA1 mutation testing
for all patients with TNBC regardless of family history and
age at diagnosis of breast cancer.
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